1. The use of a combination of a PDE5 inhibitor and a testosterone analog for the manufacture of a medicament for the treatment of female sexual dysfunction. 2. The use according to claim 1, wherein the testosterone analogue is formulated to provide a peak level of free testosterone in the circulatory system of at least 0.010 nmol / L. The use according to claim 1 or 2, wherein the testosterone analogue is provided in the form of a sublingual formulation. The use of claim 3, wherein said sublingual formulation comprises cyclodextrin, for example hydroxypropyl beta-cyclodextrin. The use according to claim 1, wherein said testosterone analogue is formulated to release substantially all of the testosterone analogue within a time interval of 60 s after administration. The use of claim 1, wherein said medicament comprises a composition comprising a testosterone analogue and a composition comprising a PDE5.7 inhibitor. The use according to claim 1, wherein said drug is a single capsule or composition with different release properties of two compounds. The use of claim 1, further comprising inhibiting adrenergic tone of the central nervous system. The use of claim 1, wherein said medicament comprises at least 5 mg of vardenafil and not more than 20 mg of vardenafil. The use of claim 1, wherein said medicament comprises at least 25 mg of sildenafil and not more than 100 mg of sildenafil. The use of claim 1, wherein said medicament comprises at least 5 mg of tadalafil and not more than 20 mg of tadalafil. The use according to claim 1, where the specified drug further includes1. Применение комбинации ингибитора ФДЭ5 и аналога тестостерона для изготовления лекарственного средства для лечения женского сексуального расстройства.2. Применение по п.1, где аналог тестостерона сформулирован для обеспечения пикового уровня свободного тестостерона в системе кровообращения, по меньшей мере, 0,010 нмоль/л.3. Применение по п.1 или 2, где аналог тестостерона обеспечивается в форме сублинг
